FDA Grants RMAT Designation to United Therapeutics' Miroliverelap for Acute Liver Failure
UTHR has more than doubled off its 52-week low of $266.98.
Summary
United Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its investigational product, Miroliverelap®, for the treatment of acute liver failure. This designation is a significant positive development, as it is granted to regenerative medicine therapies intended to treat serious or life-threatening diseases and provides for expedited development and review. The RMAT status underscores the potential of Miroliverelap® to address a critical unmet medical need and could accelerate its path to market, adding to the company's robust pipeline.
At the time of this announcement, UTHR was trading at $559.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.8B. The 52-week trading range was $266.98 to $607.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.